Could immunosignatures technology enable the development of a preventative cancer vaccine?

Luhui Shen, Debra Hansen, Stephen Johnston, Joseph B arten Legutki

Research output: Contribution to journalArticle

Abstract

The exciting prospect of developing a universal prophylactic cancer vaccine now seems more possible due to advances in technology and basic knowledge. However, the problem of testing the efficacy of such a vaccine in a clinical trial seems daunting. The low incidence and long lead-time to diagnosis of cancer would make a standard clinical trial long and expensive. Recently, we demonstrated that the immunosignatures diagnostic technology could be useful in evaluating vaccines. The technology is based on profiling the antibody diversity in an individual on a peptide chip platform. Here we propose that this technology may also enable a clinical trial of a preventative vaccine. Preliminary evidence supports the prospect of immunosignatures detecting cancer at very early stages, well before conventional diagnosis. Because the technology is simple and inexpensive, it could be used to monitor the occurrence of cancer in participants and shorten the clinical trial.

Original languageEnglish (US)
Pages (from-to)577-579
Number of pages3
JournalExpert Review of Vaccines
Volume13
Issue number5
DOIs
StatePublished - May 1 2014

Fingerprint

Cancer Vaccines
Technology
Clinical Trials
Vaccines
Antibody Diversity
Neoplasms
Peptides
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Could immunosignatures technology enable the development of a preventative cancer vaccine? / Shen, Luhui; Hansen, Debra; Johnston, Stephen; Legutki, Joseph B arten.

In: Expert Review of Vaccines, Vol. 13, No. 5, 01.05.2014, p. 577-579.

Research output: Contribution to journalArticle

@article{30894be65f274d328e85e3565b4b6f8c,
title = "Could immunosignatures technology enable the development of a preventative cancer vaccine?",
abstract = "The exciting prospect of developing a universal prophylactic cancer vaccine now seems more possible due to advances in technology and basic knowledge. However, the problem of testing the efficacy of such a vaccine in a clinical trial seems daunting. The low incidence and long lead-time to diagnosis of cancer would make a standard clinical trial long and expensive. Recently, we demonstrated that the immunosignatures diagnostic technology could be useful in evaluating vaccines. The technology is based on profiling the antibody diversity in an individual on a peptide chip platform. Here we propose that this technology may also enable a clinical trial of a preventative vaccine. Preliminary evidence supports the prospect of immunosignatures detecting cancer at very early stages, well before conventional diagnosis. Because the technology is simple and inexpensive, it could be used to monitor the occurrence of cancer in participants and shorten the clinical trial.",
author = "Luhui Shen and Debra Hansen and Stephen Johnston and Legutki, {Joseph B arten}",
year = "2014",
month = "5",
day = "1",
doi = "10.1586/14760584.2014.897616",
language = "English (US)",
volume = "13",
pages = "577--579",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Could immunosignatures technology enable the development of a preventative cancer vaccine?

AU - Shen, Luhui

AU - Hansen, Debra

AU - Johnston, Stephen

AU - Legutki, Joseph B arten

PY - 2014/5/1

Y1 - 2014/5/1

N2 - The exciting prospect of developing a universal prophylactic cancer vaccine now seems more possible due to advances in technology and basic knowledge. However, the problem of testing the efficacy of such a vaccine in a clinical trial seems daunting. The low incidence and long lead-time to diagnosis of cancer would make a standard clinical trial long and expensive. Recently, we demonstrated that the immunosignatures diagnostic technology could be useful in evaluating vaccines. The technology is based on profiling the antibody diversity in an individual on a peptide chip platform. Here we propose that this technology may also enable a clinical trial of a preventative vaccine. Preliminary evidence supports the prospect of immunosignatures detecting cancer at very early stages, well before conventional diagnosis. Because the technology is simple and inexpensive, it could be used to monitor the occurrence of cancer in participants and shorten the clinical trial.

AB - The exciting prospect of developing a universal prophylactic cancer vaccine now seems more possible due to advances in technology and basic knowledge. However, the problem of testing the efficacy of such a vaccine in a clinical trial seems daunting. The low incidence and long lead-time to diagnosis of cancer would make a standard clinical trial long and expensive. Recently, we demonstrated that the immunosignatures diagnostic technology could be useful in evaluating vaccines. The technology is based on profiling the antibody diversity in an individual on a peptide chip platform. Here we propose that this technology may also enable a clinical trial of a preventative vaccine. Preliminary evidence supports the prospect of immunosignatures detecting cancer at very early stages, well before conventional diagnosis. Because the technology is simple and inexpensive, it could be used to monitor the occurrence of cancer in participants and shorten the clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84921274822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921274822&partnerID=8YFLogxK

U2 - 10.1586/14760584.2014.897616

DO - 10.1586/14760584.2014.897616

M3 - Article

C2 - 24641768

AN - SCOPUS:84921274822

VL - 13

SP - 577

EP - 579

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 5

ER -